ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, has announced that it has entered into a broad strategic collaboration with Genosity Inc., a biotechnology company that provides expertise, software and technical solutions to unlock the power of precision medicine by advancing genomics and facilitating collaborative research.

Under the terms of the collaboration, ArcherDX will co-market Genosity's suite of consulting and laboratory software services designed to facilitate implementation and speed adoption of next-generation sequencing based testing to support precision medicine programs across biopharmaceuticals and health systems.  These services span the full lifecycle of genomic test development including assay and bioinformatics design assistance, validation planning and execution services, variant interpretation support and revenue cycle management optimization.

The software solutions covered under this collaboration include Genosity's Genome Explorer, Laboratory Information Management System (LIMS) and Cortex applications.  The Genome Explorer platform integrates with and extends ArcherDX's Archer Analysis Unlimited bioinformatics pipeline with additional Case Analyzer and Report Buildermodules that together provide an end-to-end computational analysis and result reporting solution for next-gen sequencing-based panels.  The LIMS application is designed specifically for NGS workflows to improve laboratory efficiency while enabling quality control monitoring. Pre-configuration of most of the ArcherDX assays in Genosity's LIMS facilitates easier implementation of wet lab workflows in NGS labs.  Genosity's Cortex provides a data warehouse and knowledge base that enables population-level analysis and cohort identification to support R&D and inter and intra-institution collaborations.

Financial terms of the collaboration are not being disclosed.